Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999722 | 0.86 | CYP19A1 (0.57) | CYP19A1RORC | |
| SCHEMBL5999962 | 0.85 | CYP19A1 (0.39) | CYP19A1KIF11ROCK1MEN1KMT2A | |
| SCHEMBL6000278 | 0.82 | MAPK14 (0.40) | KIF11MEN1KMT2ASMN1; SMN2GAA | |
| SCHEMBL5999689 | 0.81 | CYP19A1 (0.55) | CYP19A1MEN1KMT2A | |
| SCHEMBL5999709 | 0.81 | KIF11 (0.49) | KIF11MAPT | |
| SCHEMBL6000236 | 0.81 | KCNN4 (0.40) | CYP19A1KIF11KMT2A | |
| SCHEMBL5999440 | 0.81 | CA1 (0.38) | KIF11MAPT | |
| SCHEMBL5999690 | 0.80 | CYP19A1 (0.45) | CYP19A1SCN5ASCN9AKIF11ROCK1 | |
| SCHEMBL5999593 | 0.79 | TSHR (0.41) | CYP19A1KIF11MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6000325 | 0.75 | CYP17A1 (0.39) | CYP19A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | CYP19A1 4624/4885SCN5A 429/4885SCN9A 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.